Kiora Pharmaceuticals Files 8-K for Regulation FD Disclosure
Ticker: KPHMW · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1372514
| Field | Detail |
|---|---|
| Company | Kiora Pharmaceuticals Inc (KPHMW) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: KPRX
TL;DR
Kiora Pharma filed an 8-K for a Reg FD disclosure on Aug 13, covering events from Aug 12.
AI Summary
Kiora Pharmaceuticals, Inc. filed an 8-K on August 13, 2025, reporting a Regulation FD Disclosure. The filing details events that occurred on August 12, 2025. Kiora Pharmaceuticals, formerly Eyegate Pharmaceuticals Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates Kiora Pharmaceuticals is making a public disclosure under Regulation FD, which ensures fair disclosure of material information to all investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure, which is routine and does not inherently indicate new risks.
Key Players & Entities
- KIORA PHARMACEUTICALS INC (company) — Registrant
- EYEGATE PHARMACEUTICALS INC (company) — Former company name
- August 13, 2025 (date) — Date of report
- August 12, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure, ensuring fair and timely dissemination of material information.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 12, 2025.
What is the exact name of the registrant?
The exact name of the registrant is KIORA PHARMACEUTICALS, INC.
What was the former name of the company?
The former name of the company was EYEGATE PHARMACEUTICALS INC.
In which state was Kiora Pharmaceuticals, Inc. incorporated?
Kiora Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-12 18:00:51
Key Financial Figures
- $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che
Filing Documents
- kprx-20250813.htm (8-K) — 26KB
- kiorapharmaoverviewq3202.htm (EX-99.1) — 21KB
- kiorapharmaoverviewq3202001.jpg (GRAPHIC) — 50KB
- kiorapharmaoverviewq3202002.jpg (GRAPHIC) — 181KB
- kiorapharmaoverviewq3202003.jpg (GRAPHIC) — 65KB
- kiorapharmaoverviewq3202004.jpg (GRAPHIC) — 83KB
- kiorapharmaoverviewq3202005.jpg (GRAPHIC) — 97KB
- kiorapharmaoverviewq3202006.jpg (GRAPHIC) — 74KB
- kiorapharmaoverviewq3202007.jpg (GRAPHIC) — 34KB
- kiorapharmaoverviewq3202008.jpg (GRAPHIC) — 100KB
- kiorapharmaoverviewq3202009.jpg (GRAPHIC) — 85KB
- kiorapharmaoverviewq3202010.jpg (GRAPHIC) — 81KB
- kiorapharmaoverviewq3202011.jpg (GRAPHIC) — 83KB
- kiorapharmaoverviewq3202012.jpg (GRAPHIC) — 88KB
- kiorapharmaoverviewq3202013.jpg (GRAPHIC) — 67KB
- kiorapharmaoverviewq3202014.jpg (GRAPHIC) — 89KB
- kiorapharmaoverviewq3202015.jpg (GRAPHIC) — 52KB
- kiorapharmaoverviewq3202016.jpg (GRAPHIC) — 75KB
- kiorapharmaoverviewq3202017.jpg (GRAPHIC) — 80KB
- kiorapharmaoverviewq3202018.jpg (GRAPHIC) — 37KB
- kiorapharmaoverviewq3202019.jpg (GRAPHIC) — 101KB
- kiorapharmaoverviewq3202020.jpg (GRAPHIC) — 54KB
- kiorapharmaoverviewq3202021.jpg (GRAPHIC) — 98KB
- kiorapharmaoverviewq3202022.jpg (GRAPHIC) — 74KB
- kiorapharmaoverviewq3202023.jpg (GRAPHIC) — 106KB
- kiorapharmaoverviewq3202024.jpg (GRAPHIC) — 85KB
- kiorapharmaoverviewq3202025.jpg (GRAPHIC) — 35KB
- kprx-20250813_g1.jpg (GRAPHIC) — 341KB
- 0001372514-25-000068.txt ( ) — 3710KB
- kprx-20250813.xsd (EX-101.SCH) — 2KB
- kprx-20250813_lab.xml (EX-101.LAB) — 22KB
- kprx-20250813_pre.xml (EX-101.PRE) — 13KB
- kprx-20250813_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Kiora Pharmaceuticals, Inc. (the "Company") hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use in presentations to investors from time to time. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference. The information furnished in this report, including Exhibit 99.1, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Company Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Chief Financial Officer (Principal financial and accounting officer) Date: August 13, 2025